RE:RE:RE:'Won't find a more full pipeline for a company this size'With Chiesi now 2 1/2 years into its xB3 deal, Biodexa nominating Hunter as its lead xB3 asset with preclinical data expected in Q2, and Chiesi's potential FDA approval for its strategic Fabry asset in the first half of 2023 from both the FDA and European authorities, will Chiesi file for approval to commence an xB3 trial in 2023? Lysosomal Storage Disorders is a strategic area for Chiesi and Fabry is its key asset. A program that addresses the brain is a strategic must in this area as others also make the move. Outside of small blip in April Chiesi's partner, Protalix, is trading around its high for the year despite the carnage in biotech. Lysosomal Storage is a strategic area for Biodexa. Could we see a second deal with Chiesi and given the scientific validation and infrastructure of Biodexa a much stronger deal?
1.3000+0.1211 (+10.27%) At close: 04:00PM EST
prophetoffactz wrote: Rathjen and Saltarelli are on the Advisory Board with Chiesi overseeing Chiesi's xB3-LSD programs. The impression we are left with is that work continues. That BTI nominated Hunter as its lead xB3 asset, that Biodexa will also have Hunter as its lead xB3 program, and that Mario Salterelli is continuing and excited about the future of Biodexa would appear to argue for Chiesi's continued progress. Again, Rathjen and Saltarelli are on the Chiesi Advisory Board for Chiesi's LSD program. LSDs are a focus of xB3 research. There is a set-up for a potential second deal with Chiesi. Chiesi's strategic Fabry potential standard-of-care and billion dollar Fabry asset is now before the FDA for approval next year making Chiesi a strategic player in the LSD space. With Midatch BTI will be positioned for a much stronger deal in LSDs with Chiesis. Biodexa anticipates releasing preclinical Hunter data in the next 3-6 months as Denali continues to validate delivery to the brain. Biodexa is willing to go head-to-head with Denali's Hunter program. Confidence. The next 6 months could be interesting.